Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Autor: Cahn, PE, Cassetti, I, Losso, M, Bloch, MT, Roth, N, McMahon, J, Moore, RJ, Smith, D, Clumeck, N, Vanderkerckhove, L, Vandercam, B, Moutschen, M, Baril, J, Conway, B, Smaill, F, Smith, GHR, Rachlis, A, Walmsley, SL, Perez, C, Wolff, M, Lasso, MF, Chahin, CE, Velez, JD, Sussmann, O, Reynes, J, Katlama, C, Yazdanpanah, Y, Ferret, S, Durant, J, Duvivier, C, Poizot-Martin, I, Ajana, F, Rockstroh, JK, Faetkanheuer, G, Esser, S, Jaeger, H, Degen, O, Bickel, M, Bogner, J, Arasteh, K, Hartl, H, Stoehr, A, Rojas, EM, Arathoon, E, Gonzalez, LD, Mejia, CR, Shahar, E, Turner, D, Levy, I, Sthoeger, Z, Elinav, H, Gori, A, Monforte, A D'Arminio, Di Perri, G, Lazzarin, A, Rizzardini, G, Antinori, A, Celesia, BM, Maggiolo, F, Chow, TS, Lee, CKC, Azwa, R Iskandar Shah Raja, Mustafa, M, Oyanguren, M, Castillo, RA, Hercilla, L, Echiverri, C, Maltez, F, da Cunha, JG Saraiva, Neves, I, Teofilo, E, Serrao, R, Nagimova, F, Khaertynova, I, Orlova-Morozova, E, Voronin, E, Sotnikov, V, Yakovlev, AA, Zakharova, NG, Tsybakova, OA, Botes, ME, Mohapi, L, Kaplan, R, Rassool, MS, Arribas, JR, Gatell, JM, Negredo, E, Ortega, E, Troya, J, Berenguer, J, Aguirrebengoa, K, Antela, A, Calmy, A, Cavassini, M, Rauch, A, Stoeckle, M, Sheng, WH, Lin, HH, Tsai, HC, Changpradub, D, Avihingsanon, A, Kiertiburanakul, S, Ratanasuwan, W, Nelson, MR, Clarke, A, Ustianowski, A, Winston, A, Johnson, MA, Asmuth, DM, Cade, J, Gallant, JE, Ruane, PJ, Kumar, PN, Luque, AE, Panther, L, Tashima, KT, Ward, D, Berger, DS, Dietz, CA, Fichtenbaum, C, Gupta, S, Mullane, KM, Novak, RM, Sweet, DE, Crofoot, GE, Hagins, DP, Lewis, ST, McDonald, CK, DeJesus, E, Sloan, L, Prelutsky, DJ, Rondon, JC, Henn, S, Scarsella, AJ, Morales, JO, Ramirez, Santiago, L, Zorrilla, CD, Saag, MS, Hsiao, CB, Cahn, Pedro, Kaplan, Richard, Sax, Paul E, Squires, Kathleen, Molina, Jean-Michel, Avihingsanon, Anchalee, Ratanasuwan, Winai, Rojas, Evelyn, Rassool, Mohammed, Bloch, Mark, Vandekerckhove, Linos, Ruane, Peter, Yazdanpanah, Yazdan, Katlama, Christine, Xu, Xia, Rodgers, Anthony, East, Lilly, Wenning, Larissa, Rawlins, Sandy, Homony, Brenda, Sklar, Peter, Nguyen, Bach-Yen, Leavitt, Randi, Teppler, Hedy

Publikováno v: In The Lancet HIV November 2017 4(11):e486-e494

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Significance of polymorphism in 2’,5’-oligoadenylate synthetase genes in HIV infection

Autor: Bakhteeva L., Khaibullina S., Lombardi V., Anokhin V., Rizvanov A., Boichuk S., Nagimova F.

Publikováno v: SCOPUS20764243-2016-8-1-SID84962040393

© 2016, Nizhny Novgorod State Medical Academy. All rights reserved.The aim of the investigation was to assess the prognostic value of polymorphism of genes encoding 2’,5’-oligoadenylate synthetase (OAS) synthesis in HIV infection. Materials and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4660f67a27296153a884eb8e7a0dfe61
https://openrepository.ru/article?id=52436

P1175 CEPEGINTERFERON-ALFA-2b IN COMBINATION WITH RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C

Autor: Znoyko, O., Klimova, E., Maximov, S., Kizhlo, S., Petrochenkova, N., Nagimova, F., Linkova, Y., Ivanov, R., Chernovskaya, T.

Publikováno v: In Journal of Hepatology April 2014 60(1) Supplement:S476-S476

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.